



### Amendments to the Claims

The listing of claims will replace all prior versions of claims in the application.

#### **Listing of Claims:**

1 (Currently amended). A compound of Formula (I) or (II)



wherein

A is nitrogen and B is carbon;

R<sup>0</sup> is an aryl optionally substituted with one or more substituents or a heteroaryl optionally substituted with one or more substituents;

R<sup>1</sup> is aryl optionally substituted with one or more substituents, heteroaryl optionally substituted with one or more substituents,  $-\text{CH}=\text{CH}-\text{R}^{1a}$ , or  $-\text{CH}_2\text{CH}_2-\text{R}^{1a}$ , where R<sup>1a</sup> is hydrogen or a chemical moiety selected from a (C<sub>1</sub>-C<sub>8</sub>)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring(s), 3- to 6-membered partially or fully saturated heterocycle, aryl, heteroaryl, where the chemical moiety is optionally substituted with one or more substituents;

X is a bond;

R<sup>3a</sup> and R<sup>3b</sup> are each independently hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl; and

R<sup>4</sup> is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents; or a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound, or said salt;

provided that when the compound is a compound of Formula (II), R<sup>3a</sup> and R<sup>3b</sup> are not both hydrogen when X is a bond.

2 (Currently amended). The compound of Claim 1 wherein R<sup>4</sup> is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, and 3- to 8-membered partially or fully saturated carbocyclic ring(s), and 3- to 8-membered partially or fully saturated heterocycle,

where said chemical moiety is optionally substituted with one or more substituents; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

3 (Currently amended). The compound of Claim 2 wherein R<sup>4</sup> is (C<sub>1</sub>-C<sub>8</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>8</sub>)alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-4-yl ~~morpholin-1-yl~~; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

4 (Currently amended). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (I); or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

5-6 (Cancelled).

7 (Currently amended). The compound of Claim 4 wherein R<sup>0</sup> and R<sup>1</sup> are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, ~~(C<sub>1</sub>-C<sub>4</sub>)alkyl~~, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

8 (Currently amended). The compound of Claim 7 wherein R<sup>0</sup> and R<sup>1</sup> are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, ~~(C<sub>1</sub>-C<sub>4</sub>)alkyl~~, fluoro-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

9 (Currently amended). The compound of Claim 8 wherein R<sup>0</sup> is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and R<sup>1</sup> is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

- 10 (Currently amended). The compound of Claim 4 selected from the group consisting of  
2-(2-chloro-phenyl)-5-isopropyl-3-(4-methoxy-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one;  
2-(2-chloro-phenyl)-5-isopropyl-3-(4-cyano-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-  
one;  
2-(2-chloro-phenyl)-5-isopropyl-3-(4-chloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-  
4-one;  
3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one;  
3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-cyclohexyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-  
4-one;  
3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-isopropyl-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one;  
3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-  
pyrrolo[3,4-c]pyrazol-4-one;  
3-(4-chloro-phenyl)-5-cyclohexyl-2-(2,4-dichloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one;  
3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-isopropyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-  
4-one;  
3-(4-cyano-phenyl)-2-(3-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one;  
3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one; and  
3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-cyclohexyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-  
4-one; or a pharmaceutically acceptable salt thereof.  
~~or a solvate or hydrate of said compound.~~
- 11 (Currently amended). The compound of Claim 10 selected from the group consisting of  
2-(2-chloro-phenyl)-5-isopropyl-3-(4-cyano-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-  
one;  
2-(2-chloro-phenyl)-5-isopropyl-3-(4-chloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-  
4-one; and  
3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-  
c]pyrazol-4-one; or a pharmaceutically acceptable salt thereof.  
~~or a solvate or hydrate of said compound.~~

12-29 (Cancelled).

30 (Currently amended). The compound of Claim 4 wherein  $R^1$  is  $-\text{CH}=\text{CH}-R^{1a}$ , or  $-\text{CH}_2\text{CH}_2-R^{1a}$ , where  $R^{1a}$  is ~~hydrogen or~~ a chemical moiety selected from ~~(C<sub>1</sub>-C<sub>8</sub>)alkyl~~, 3- to 8-membered partially or fully saturated carbocyclic ring(s), 3- to 6-membered partially or fully saturated heterocycle, aryl, heteroaryl, where the chemical moiety is optionally substituted with one or more substituents; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

31 (Currently amended). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (II); or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

32-33 (Cancelled).



34 (Currently amended). The compound of Claim 31 wherein  $R^0$  and  $R^1$  are each independently a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, ~~(C<sub>1</sub>-C<sub>4</sub>)alkyl~~, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

35 (Currently amended). The compound of Claim 34 wherein  $R^0$  and  $R^1$  are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, ~~(C<sub>1</sub>-C<sub>4</sub>)alkyl~~, fluoro-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

36 (Currently amended). The compound of Claim 35 wherein  $R^0$  is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and  $R^1$  is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt.~~

37-41 (Cancelled).

42 (Currently amended). A compound of Formula (III) or (IV)



wherein

A is nitrogen and B is carbon;

R<sup>0a</sup>, R<sup>0b</sup>, R<sup>1a</sup>, and R<sup>1b</sup>, and R<sup>1c</sup> are each independently halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, or cyano;

n and m are each independently 0, 1 or 2;

X is a bond;

R<sup>3a</sup> and R<sup>3b</sup> are each independently hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl; and

R<sup>4</sup> is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents; or

a pharmaceutically acceptable salt thereof, ~~a solvate or hydrate of said compound or said salt~~;

provided that when said compound is a compound of Formula (IV), R<sup>3a</sup> and R<sup>3b</sup> are not both hydrogen ~~when X is a bond~~.

43 (Currently amended). The compound of Claim 42 wherein said compound is a compound of Formula (III); or a pharmaceutically acceptable salt thereof, ~~a solvate or hydrate of said compound or said salt~~.

44-48 (Cancelled).

49 (Currently amended). The compound of Claim 42 wherein said compound is a compound of Formula (IV); or a pharmaceutically acceptable salt thereof, ~~a solvate or hydrate of said compound or said salt~~.

50-54 (Cancelled).

55 (Currently amended). A pharmaceutical composition comprising (1) a compound of Claim 1, ~~or a solvate or hydrate of said compound or said salt~~; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

56-58 (Cancelled).

59 (Currently amended). A method for treating obesity comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1; or a pharmaceutically acceptable salt thereof, ~~or a solvate or hydrate of said compound or said salt~~.

60-63 (Cancelled).

64 (Previously presented). A method for treating obesity comprising the step of administering a pharmaceutical composition of Claim 55.

65-73 (Cancelled).